# VCapital

> VCapital is a VC fund in Chicago backing Health Care and Software. See 19 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chicago, United States
- Total investments: 19
- Last investment: Jun 2026
- Lead investor: 58%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/vcapital/
- Website: http://www.vcapital.com

VCapital is a VC fund in Chicago focused on Health Care and Software. With an in-depth focus on research and exceptional due diligence plus a 30-year track record, VCapital Management Co. identifies early-stage, institutional-quality venture capital opportunities with potential to grow, succeed, and deliver returns to investors. Operational support and active guidance are provided to entrepreneurs for increasingchances for a successful outcome. Of particular interest are technology, medical, and science-related deals where growth potential is greatest. Employing a concierge and flexible service structure for investors, the VCapital team guides professional investment advisors and individuals who seek to add venture capital to diversify portfolios, manage risk, and meet wealth management goals.

## Contacts

5 contacts available for VCapital. Shizune tracks 5 team members at VCapital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/vcapital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 26% |
| Software | 4 | 21% |
| Biotechnology | 4 | 21% |
| Medical Device | 3 | 16% |
| Medical | 2 | 11% |

43 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 37% |
| Series B | 4 | 21% |
| Seed | 2 | 11% |
| Venture - Series Unknown | 2 | 11% |
| Convertible Note | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| James Vaughan | Co-founder, Chief Investor Relations Officer, Board Member | 0 | https://shizune.co/investors/profile/james-vaughan |
| Len Batterson | Founder, Chairman and CEO | 0 | https://shizune.co/investors/profile/len-batterson |
| Ryan Kole | Sr. Investment Analyst & Partner | 4 | https://shizune.co/investors/profile/ryan-kole |
| Chris LoPresti | Venture Strategist | 0 | https://shizune.co/investors/profile/chris-lopresti |
| Richard McMenamin | Vice President, Business Development | 0 | https://shizune.co/investors/profile/richard-mcmenamin-c618 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rejuvenate Bio | Rejuvenate Bio is a biotechnology company that develops novel gene therapies for dogs. The company's therapy provides a solution for the mitral valve disease to stop the progression of heart failure in dogs, thus providing pets with extended overall health and maximal lifespan. It was founded in 2017 and is based in San Diego, CA. | $6M | Venture - Series Unknown | Jun 08, 2026 |  |
| SentiAR | SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $8.5M | Series B | Apr 11, 2023 |  |
| ATLAS Space Operations | ATLAS Space Operations is the Satellite Communications as a Service Getting Your Data, Faster | $26M | Series B | Aug 25, 2022 |  |
| Avenda Health | Avenda Health has built a multi-modal AI decision support platform to bring superhuman abilities to cancer surgeons and oncologists power the future of cancer care. Our FDA-cleared inference engine, Unfold AI, build synthetic spatial maps of cancer incorporating the totality of a patient's diagnostic data (imaging, pathology, biomarkers,clinical information) and reveals invisible tumor extent to guide patients and their physicians to improve clinical decision making and outcomes. | $10M | Series B | Aug 25, 2022 |  |
| EeroQ | EeroQ is a quantum hardware start-up based in New York and Lansing, Michigan. | $7.3M | Seed | Aug 23, 2022 |  |
| InRule Technology | InRule Technology enables enterprises to understand and automate decisions with unparalleled speed, agility, accuracy, and transparency. |  | Venture - Series Unknown | Jun 08, 2021 |  |
| SentiAR | SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $5.1M | Series A | Apr 13, 2021 |  |
| Rejuvenate Bio | Rejuvenate Bio is a biotechnology company that develops novel gene therapies for dogs. The company's therapy provides a solution for the mitral valve disease to stop the progression of heart failure in dogs, thus providing pets with extended overall health and maximal lifespan. It was founded in 2017 and is based in San Diego, CA. | $14.6M | Series A | Apr 12, 2021 |  |
| Ocient | Ocient is a startup building a near-real-time database and data analytics platform for petabyte- to exabyte-scale data sets. Ocient was founded by the talent behind the largest software startup exit in Chicago’s history. Ocient is a well-funded company, with an engineering team comprised of brilliant computer scientists hailing from the world’s topuniversities and organizations. | $40M | Series B | Jan 25, 2021 |  |
| Ocient | Ocient is a startup building a near-real-time database and data analytics platform for petabyte- to exabyte-scale data sets. Ocient was founded by the talent behind the largest software startup exit in Chicago’s history. Ocient is a well-funded company, with an engineering team comprised of brilliant computer scientists hailing from the world’s topuniversities and organizations. |  | Series B | Jan 15, 2021 |  |

10 of 19 investments shown.

## Co-investors
- [Harmonix Fund](https://shizune.co/investors/profile/harmonix-fund) — VC Fund, 3 deals together
- [Harmonix Fund](https://shizune.co/investors/profile/neue-fund) — VC Fund, 3 deals together
- [B Capital](https://shizune.co/investors/profile/b-capital-group) — VC Fund, 2 deals together
- [Boomerang-Catapult](https://shizune.co/investors/profile/boomerang-catapult) — VC Fund, 2 deals together
- [Cultivation Capital](https://shizune.co/investors/profile/cultivation-capital) — VC Fund, 2 deals together
- [Digitalis Ventures](https://shizune.co/investors/profile/digitalis-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does VCapital invest in?

VCapital invests primarily in Health Care, Software and Biotechnology startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact VCapital?

Public channels for VCapital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at VCapital?

The team at VCapital includes James Vaughan (Co-founder, Chief Investor Relations Officer, Board Member), Len Batterson (Founder, Chairman and CEO) and Ryan Kole (Sr. Investment Analyst & Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co